ReviewMycopathologia2008
Phenotypic switching of Cryptococcus neoformans and Cryptococcus gattii.
Review in Mycopathologia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Unveiling the menace: a thorough review of potential pandemic fungal disease.Frontiers in fungal biology · 2024Review
- The need for environmental surveillance to understand the ecology, epidemiology and impact of Cryptococcus infection in Africa.FEMS microbiology ecology · 2021Review
- Clonal Dispersal ofJournal of fungi (Basel, Switzerland) · 2019Article
- Evaluation ofFrontiers in microbiology · 2019Article
- Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans.Fungal genetics and biology : FG & B · 2015Review
- Molecular Epidemiology of Clinical Cryptococcus neoformans Isolates in Seoul, Korea.Mycobiology · 2014Article
- Fungal alternative splicing is associated with multicellular complexity and virulence: a genome-wide multi-species study.DNA research : an international journal for rapid publication of reports on genes and genomes · 2014Article
- DNA mutations mediate microevolution between host-adapted forms of the pathogenic fungus Cryptococcus neoformans.PLoS pathogens · 2012Article
- Emerging themes in cryptococcal capsule synthesis.Current opinion in structural biology · 2011Review
- In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.Molecular immunology · 2011Article
- How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.Annual review of microbiology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microorganisms that live in fluctuating environments must constantly adapt their behavior to survive. The host constitutes an important microenvironment in opportunistic and primary fungal pathogens like Cryptococcus neoformans (C. neoformans) and Cryptococcus gattii (C. gattii). In clonal populations, adaptation may be achieved through the generation of diversity. For fungi phenotype switching constitutes a mechanism that allows them to change rapidly. Both C. neoformans and C. gattii undergo phenotypic switching, which allows them to be successful pathogens and cause persistent disease. Similar to other encapsulated microbes that exhibit phenotypic variation, phenotypic switching in Cryptococcus changes the polysaccharide capsule. Most importantly, in animal models phenotypic switching affects virulence and can change the outcome of infection. Virulence changes because C. neoformans and C. gattii switch variants elicit different inflammatory responses in the host. This altered host response can also affect the response to antifungal therapy and in some cases may even promote the selection of switch variants. This review highlights the similarity and differences between phenotypic switching in C. neoformans and C. gattii, the two dominant species that cause cryptococcosis in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.